vs

Side-by-side financial comparison of Moderna (MRNA) and REPUBLIC AIRWAYS HOLDINGS INC. (RJET). Click either name above to swap in a different company.

REPUBLIC AIRWAYS HOLDINGS INC. is the larger business by last-quarter revenue ($1.1B vs $1.0B, roughly 1.1× Moderna). Over the past eight quarters, REPUBLIC AIRWAYS HOLDINGS INC.'s revenue compounded faster (3.9% CAGR vs -45.0%).

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Republic Airways Holdings Inc. is an American airline holding company based in Indianapolis, Indiana. The company owns two regional airlines, Mesa Airlines and Republic Airways. Together the two airlines operate the world's largest fleet of Embraer 170 and Embraer 175 aircraft. The majority of the shares of company are owned by the mainline carriers that contract with Republic, American Airlines Group, Delta Air Lines, and United Airlines.

MRNA vs RJET — Head-to-Head

Bigger by revenue
RJET
RJET
1.1× larger
RJET
$1.1B
$1.0B
MRNA
Faster 2-yr revenue CAGR
RJET
RJET
Annualised
RJET
3.9%
-45.0%
MRNA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
MRNA
MRNA
RJET
RJET
Revenue
$1.0B
$1.1B
Net Profit
$-200.0M
Gross Margin
79.6%
Operating Margin
-25.6%
22.0%
Net Margin
-19.7%
Revenue YoY
-45.4%
Net Profit YoY
-1638.5%
EPS (diluted)
$-0.51
$3.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRNA
MRNA
RJET
RJET
Q4 25
$1.1B
Q3 25
$1.0B
$90.7M
Q2 25
$92.8M
Q1 25
$94.7M
Q4 24
$966.0M
$808.3M
Q3 24
$1.9B
Q2 24
$110.8M
Q1 24
$131.6M
Net Profit
MRNA
MRNA
RJET
RJET
Q4 25
Q3 25
$-200.0M
$-14.1M
Q2 25
$20.9M
Q1 25
$-58.6M
Q4 24
$-1.1B
$97.8M
Q3 24
$13.0M
Q2 24
$-19.9M
Q1 24
$11.7M
Gross Margin
MRNA
MRNA
RJET
RJET
Q4 25
Q3 25
79.6%
Q2 25
Q1 25
Q4 24
23.5%
Q3 24
72.4%
Q2 24
Q1 24
Operating Margin
MRNA
MRNA
RJET
RJET
Q4 25
22.0%
Q3 25
-25.6%
-10.1%
Q2 25
-0.2%
Q1 25
-60.4%
Q4 24
-129.0%
18.7%
Q3 24
-3.8%
Q2 24
-8.1%
Q1 24
8.8%
Net Margin
MRNA
MRNA
RJET
RJET
Q4 25
Q3 25
-19.7%
-15.6%
Q2 25
22.5%
Q1 25
-61.9%
Q4 24
-115.9%
12.1%
Q3 24
0.7%
Q2 24
-18.0%
Q1 24
8.9%
EPS (diluted)
MRNA
MRNA
RJET
RJET
Q4 25
$3.13
Q3 25
$-0.51
$-0.34
Q2 25
$0.50
Q1 25
$-1.42
Q4 24
$-2.91
$2.42
Q3 24
$0.03
Q2 24
$-0.48
Q1 24
$0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRNA
MRNA
RJET
RJET
Cash + ST InvestmentsLiquidity on hand
$1.1B
$296.5M
Total DebtLower is stronger
$882.9M
Stockholders' EquityBook value
$9.3B
$1.3B
Total Assets
$12.1B
$3.3B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRNA
MRNA
RJET
RJET
Q4 25
$296.5M
Q3 25
$1.1B
$38.7M
Q2 25
$42.5M
Q1 25
$54.1M
Q4 24
$1.9B
$302.0M
Q3 24
$1.6B
Q2 24
$16.3M
Q1 24
$18.5M
Total Debt
MRNA
MRNA
RJET
RJET
Q4 25
$882.9M
Q3 25
$27.0M
Q2 25
$28.2M
Q1 25
$31.7M
Q4 24
$752.2M
Q3 24
Q2 24
$287.7M
Q1 24
$299.0M
Stockholders' Equity
MRNA
MRNA
RJET
RJET
Q4 25
$1.3B
Q3 25
$9.3B
$-52.6M
Q2 25
$-38.7M
Q1 25
$-59.8M
Q4 24
$10.9B
$1.1B
Q3 24
$11.9B
Q2 24
$134.9M
Q1 24
$154.7M
Total Assets
MRNA
MRNA
RJET
RJET
Q4 25
$3.3B
Q3 25
$12.1B
$158.9M
Q2 25
$178.6M
Q1 25
$215.0M
Q4 24
$14.1B
$2.8B
Q3 24
$15.8B
Q2 24
$664.4M
Q1 24
$706.3M
Debt / Equity
MRNA
MRNA
RJET
RJET
Q4 25
0.66×
Q3 25
Q2 25
Q1 25
Q4 24
0.68×
Q3 24
Q2 24
2.13×
Q1 24
1.93×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRNA
MRNA
RJET
RJET
Operating Cash FlowLast quarter
$-847.0M
Free Cash FlowOCF − Capex
$-880.0M
FCF MarginFCF / Revenue
-86.6%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRNA
MRNA
RJET
RJET
Q4 25
Q3 25
$-847.0M
Q2 25
$-9.4M
Q1 25
Q4 24
$825.0M
$184.0M
Q3 24
$-1.6B
Q2 24
$11.2M
Q1 24
Free Cash Flow
MRNA
MRNA
RJET
RJET
Q4 25
Q3 25
$-880.0M
Q2 25
$-10.5M
Q1 25
Q4 24
$303.0M
$-42.7M
Q3 24
$-1.7B
Q2 24
$7.5M
Q1 24
FCF Margin
MRNA
MRNA
RJET
RJET
Q4 25
Q3 25
-86.6%
Q2 25
-11.3%
Q1 25
Q4 24
31.4%
-5.3%
Q3 24
-92.2%
Q2 24
6.8%
Q1 24
Capex Intensity
MRNA
MRNA
RJET
RJET
Q4 25
Q3 25
3.2%
Q2 25
1.2%
Q1 25
Q4 24
54.0%
28.0%
Q3 24
8.1%
Q2 24
3.4%
Q1 24
Cash Conversion
MRNA
MRNA
RJET
RJET
Q4 25
Q3 25
Q2 25
-0.45×
Q1 25
Q4 24
1.88×
Q3 24
-120.46×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

RJET
RJET

United Airlines$517.5M48%
Delta Air Lines$409.7M38%
Other$49.9M5%
Republic Airways Holdings Inc.$42.2M4%
Other Airlines$25.7M2%
LIFT Academy$23.2M2%

Related Comparisons